Epilepsy encompasses a group of heterogeneous brain diseases that affect more than 50
million people worldwide. Epilepsy may have discernible structural, infectious, metabolic …

Novel and effective antiseizure medications are needed to treat refractory and rare forms of
epilepsy. Cannabinoids, which are obtained from the cannabis plant, have a long history of …

Abstract The International League Against Epilepsy (ILAE) Task Force on Nosology and
Definitions proposes a classification and definition of epilepsy syndromes in the neonate …

Objective Add‐on cannabidiol (CBD) significantly reduced seizures associated with Dravet
syndrome (DS) in a randomized, double‐blind, placebo‐controlled trial: GWPCARE1 Part B …

Background: SCN1A is one of the most common epilepsy genes. About 80% of SCN1A
gene mutations cause Dravet syndrome (DS), which is a severe and catastrophic epileptic …

The high pace of gene discovery has resulted in thrilling advances in the field of epilepsy
genetics. Clinical testing with comprehensive gene panels, exomes, or genomes are now …

Dravet syndrome (DS) is a severe, rare, and complex developmental and epileptic
encephalopathy affecting 1 in 16 000 live births and characterized by a drug‐resistant …

Cannabis-derived cannabinoids have neuroactive properties. Recently, there has been
emerging interest in the use of cannabidiol (CBD)-enriched products for treatment of drug …

The last decade saw impressive advances not only in the discovery of gene mutations
causing epilepsy, but also in unraveling the molecular mechanisms underlying the clinical …

Abstract Introduction Both Δ9 Tetrahydrocannabidiol (THC) and cannabidiol (CBD)
components of cannabis, have been shown to have anticonvulsant effects. Cannabis oils …